Searched for
ARUN CHANDAVARKAR
Biocon Biologics appoints Shreehas Tambe as MD & CEOTambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build an...- Biocon Biologics interchangeable insulin Semglee gets US FDA approvalBiocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...
- Biocon Biologics provided 7,000 doses of Itolizumab in AprilThe company does not look at Covid-19 related drugs as a business opportunity; it expects higher growth this fiscal year on the back of new...
- Biocon Biologics promotes Shreehas Tambe as deputy CEOA Biocon veteran, Shreehas Tambe joined the company in 1997 and has more than 20 years of leadership experience in operational and strategi...
- Biocon elevates Siddharth Mittal as CEO and joint MDMittal takes over from Arun Chandavarkar who retired as chief executive and joint MD of the company on November 30.
- Buy Biocon, target Rs 660: Manas JaiswalBuy Biocon Ltd. at a price target of Rs 660.0 and a stop loss at Rs 630 from the entry point.
- Buy Biocon, target Rs 625: Manas JaiswalBuy Biocon Ltd. at a price target of Rs 625.0 and a stop loss at Rs 594 from entry point.
- Buy Biocon, target Rs 668: Kunal BothraBuy Biocon Ltd. at a price target of Rs 668.0 and a stop loss at Rs 622 from entry point.
- Buy Biocon, target Rs 642: Jay ThakkarBuy Biocon Ltd. at a price target of Rs 642.0 and a stop loss at Rs 606 from entry point.
- Buy Biocon, target Rs 641: Dr CK NarayanBuy Biocon Ltd. at a price target of Rs 641.0 and a stop loss at Rs 620 from entry point.
- Mylan-Biocon's breast cancer biosimilar gets ANVISA nodBiosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.
- Biocon introduces oncologic biosimilar KRABEVA in IndiaThe biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervic...
- See full recovery from GST impact in second half of 2017: Arun Chandavarkar, BioconIn order to recover in terms of to compensate or offset these costs through revenues in Malaysia we had guided that as and when initially w...
- Buy Biocon Ltd. target Rs 1234.0 : Rakesh BansalBuy Biocon Ltd. at a price target of Rs 1234.0 and a stoploss at Rs 1107.0 from entry point
- Mylan and Biocon make USFDA submission for proposed biosimilar trastuzumabThe submitted BLA includes a comprehensive package of analytical similarity, nonclinical and clinical data that consists of two pharmacokin...
- European Medicines Agency accepts marketing application of Biocon, Mylan productMylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.
- Biocon, Mylan drug discovery programme to treat cancer, arthritis makes progressBiocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3...
- Biocon posts 15% rise in revenue, names new CEOBiocon, the country's largest biotech company, reported a 15% rise in fourth-quarter revenue to 746 crore, helped by a 17% rise in sales at...
- Biocon Q4 Net dips 54 per cent at Rs 113 croreFor the year ended March 31, 2014, the company's net profit declined by 18.69 per cent to Rs 413.72 crore from Rs 508.82 crore in the 2012-...
- Clinical trials for oral insulin to enter phase two: BioconAfter the success of its recomibant human insulin "Insugen", Biocon said clinical trials for the oral insulin would soon enter phase two.
Load More
